PLA2G7 and neoplasm: In vivo, once tumours were palpable, C26 tumour‐bearing mice were treated once daily either with a vehicle solution or darapladib at a dose that efficiently inhibited circulating PLA2G7 activity over 24 h (FigureS5D,21, 22).